Tvardi Therapeutics Inc (fra:69C) Share Price

Company Profile

Business description
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
Contact
3 Sugar Creek Center boulevard
Suite 525
Sugar LandTX77478
USA
T: +1 713 489-8654
https://www.tvarditherapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
12

Recommended

Strong demand for AI infrastructure drives fair value lift.

Roy Van Keulen | 30 September 2026

Investors in cheap ASX share with a narrow moat enjoys a high yield, but there are risks investors should be aware of.

Morningstar | 28 September 2026

Trading at an 18% discount, this wide-moat stock is a rare find.

Malik Ahmed Khan, CFA | 22 September 2026

Index	Last price	Change	% Change
All Ordinaries	8,969.20	82.60	0.93%
CAC 40	7,964.51	71.36	-0.89%
DAX 40	25,199.19	200.02	-0.79%
Dow JONES (US)	50,906.05	443.87	-0.86%
FTSE 100	10,606.00	30.71	-0.29%
HKSE	24,613.27	89.70	0.37%
NASDAQ	26,861.06	63.52	0.24%
Nikkei 225	66,753.72	1,272.45	1.94%
NZX 50 Index	13,784.03	50.36	-0.36%
S&P 500	7,651.54	19.30	-0.25%
S&P/ASX 200	8,789.30	80.00	0.92%
SSE Composite Index	3,842.19	11.74	0.31%